Literature DB >> 18363814

Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.

K Ovlisen1, A T Kristensen, L A Valentino, N Hakobyan, J Ingerslev, M Tranholm.   

Abstract

BACKGROUND: Hemophilia A is the most common serious bleeding disorder, and the hallmark of this disease is joint bleeding episodes. These result in hemophilic synovitis, an inflammatory and proliferative condition of the joint, which progresses into a chronic degenerative arthritis, hemophilic arthropathy.
METHODS: In this paper, we describe the effect of recombinant factor VIIa (rFVIIa), and an analogue NN1731 as well as rFVIII on needle-induced bleeding in hemophilia A mice.
CONCLUSIONS: Here we show a reducing effect of rFVIIa and NN1731 on bleeding induced in hemophilic mice, and we show that preventive treatment with rFVIII normalizes bleeding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363814     DOI: 10.1111/j.1538-7836.2008.02954.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.

Authors:  N Narkbunnam; J Sun; G Hu; F-C Lin; T A Bateman; M Mihara; P E Monahan
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

2.  Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

Authors:  Junjiang Sun; Baolai Hua; Eric W Livingston; Sarah Taves; Peter B Johansen; Maureane Hoffman; Mirella Ezban; Dougald M Monroe; Ted A Bateman; Paul E Monahan
Journal:  Blood       Date:  2016-12-30       Impact factor: 22.113

3.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27

4.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

Review 5.  Novel treatments for hemophilia through rebalancing of the coagulation cascade.

Authors:  Yakun Zhao; Angela C Weyand; Jordan A Shavit
Journal:  Pediatr Blood Cancer       Date:  2021-02-12       Impact factor: 3.167

6.  Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Authors:  Raja Prince; Luca Bologna; Mirko Manetti; Daniela Melchiorre; Irene Rosa; Natacha Dewarrat; Silvia Suardi; Poorya Amini; José A Fernández; Laurent Burnier; Claudia Quarroz; Maria Desiré Reina Caro; Yasuhiro Matsumura; Johanna A Kremer Hovinga; John H Griffin; Hans-Uwe Simon; Lidia Ibba-Manneschi; François Saller; Sara Calzavarini; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2018-01-09       Impact factor: 25.476

7.  Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention.

Authors:  M Tranholm; A T Kristensen; M L Broberg; M P Groth
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

8.  Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels.

Authors:  Klytaimnistra Kiouptsi; Alexandra Grill; Amrit Mann; Mareike Döhrmann; Maren Lillich; Sven Jäckel; Frano Malinarich; Henning Formes; Davit Manukyan; Saravanan Subramaniam; Avinash Khandagale; Cornelia Karwot; Serge C Thal; Markus Bosmann; Inge Scharrer; Kerstin Jurk; Christoph Reinhardt
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.